Abstract
Uterine sarcomas are rare, highly malignant tumours comprising < 1 % of all gynaecologic malignancies. To evaluate clinical presentation, histolopathologic pattern and outcome of uterine sarcomas presenting to a tertiary referral centre over an 8 year period (2004–2012). All histologically proven uterine sarcomas were retrospectively analysed. Clinical presentation, histology, treatment and outcome were analysed. Mean age was 42 years. Predominant histopathology was endometrial stromal sarcoma (n = 13); 9 were low grade, carcinosarcoma (n = 8) and leiomyosarcoma (n = 2). Fourteen patients had Stage I disease, 3 Stage II, 4 Stage III and 2 were Stage IV at presentation. Patients with disease confined to uterus received no adjuvant treatment (61 %). Of these, 11 were endometrial stromal sarcoma (7 were low grade) and 3 were carcinosarcomas. Four patients received adjuvant EBRT following hysterectomy (17 %). Two patients who presented with metastases received palliative chemotherapy. Mean follow-up period was 46 months (0–86 months). Eleven patients (47 %) developed disease recurrence. Seven (30 %) had local recurrence, while 4 (17 %) developed pulmonary metastases. A total of eight patients died and all deaths were within 1 year of recurrence. The only prognostic factor that correlated with survival was the stage of disease at diagnosis.
Similar content being viewed by others
References
Sharma DN, Rath GK, Kumar S, Kumar L, Bhatla N, Gandhi AK, Hariprasad R (2011) Clinical outcome of patients with uterine sarcomas. J Cancer Res Ther 7:270–274
Naaman Y, Shveiky D, Ben-Shachar I, Shushan A, Mejia-Gomez J, Benshushan A (2011) Uterine sarcoma: prognostic factors and treatment evaluation. IMAJ 13:76–79
Durnali A, Tokluoğlu S, Özdemir N, Inanç M, Alkiş N, Zengin N, Sönmez ÖU, Küçüköner M (2012) Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey. Asian Pac J Cancer Prev 13(5):1935–1941
Nassar OA, Abdul Moaty SB, Khalil e-SA, El-Taher MM, El Najjar M (2010) Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst 22(2):113–122
Prat J (2009) FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 104(3):177–178
Shah JP, Bryant CS, Kumar S et al (2008) Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol 112:1102
Wright JD, Seshan VE, Shah M et al (2008) The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol 199(5):536.e1–536.e8
Puliyath G, Krishnan Nair M (2012) Endometrial stromal sarcoma: a review of the literature. Indian J Med Paediatr Oncol 33(1):1–6
D’Angelo E, Prat J (2010) Uterine sarcomas: a review. Gynecol Oncol 116(1):131–139
Naaman Y, Shveiky D, Ben-Shachar I, et al (2011) Uterine sarcoma: prognostic factors and treatment evaluation. IMAJ 13(2):76–79
Barakat RR. Principles and practice of gynecological oncology
Homesley HD, Filiaci V, Markman M, Gynecologic Oncology Group et al (2007) Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a gynecologic oncology group study. J Clin Oncol 25:526–531
Anupama R, Kuriakose S et al (2013) Carcinosarcoma of the uterus—a single institution retrospective analysis of the management and outcome and a brief review of literature. Indian J Surg Oncol 4(3):222–228
Conflict of Interest
The authors declare that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sivakumari, S., Rajaraman, R. & Subbiah, S. Uterine Sarcoma: The Indian Scenario. Indian J Surg Oncol 6, 232–236 (2015). https://doi.org/10.1007/s13193-015-0433-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13193-015-0433-9